Sanofi Updates Tolebrutinib Regulatory Submission
Ticker: SNYNF · Form: 6-K · Filed: Dec 29, 2025 · CIK: 1121404
| Field | Detail |
|---|---|
| Company | Sanofi (SNYNF) |
| Form Type | 6-K |
| Filed Date | Dec 29, 2025 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 1 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: regulatory-update, pharmaceuticals, drug-submission
TL;DR
Sanofi filed a 6-K on Dec 24, 2025, updating the market on its tolebrutinib drug submission for MS.
AI Summary
On December 24, 2025, Sanofi announced an update regarding its tolebrutinib regulatory submission for non-relapsing secondary progressive multiple sclerosis. The company is providing this information as part of its reporting requirements for the month of December 2025.
Why It Matters
This filing provides a regulatory update on a key drug candidate, which could impact future revenue streams and patient treatment options for multiple sclerosis.
Risk Assessment
Risk Level: low — This is a routine filing providing an update on a regulatory submission, not a material financial event.
Key Players & Entities
- Sanofi (company) — Registrant
- tolebrutinib (drug) — Subject of regulatory submission
- December 24, 2025 (date) — Date of press release
- non-relapsing secondary progressive multiple sclerosis (medical_condition) — Indication for tolebrutinib
FAQ
What is the specific nature of the update regarding tolebrutinib?
The filing states that Sanofi published a press release on December 24, 2025, providing an update on the tolebrutinib regulatory submission for non-relapsing secondary progressive multiple sclerosis.
What form is this SEC filing?
This is a Form 6-K report of a foreign private issuer.
What is the filing period for this report?
The conformed period of report is December 2025.
What is Sanofi's primary business classification?
Sanofi's Standard Industrial Classification is Pharmaceutical Preparations [2834].
Where is Sanofi's principal executive office located?
Sanofi's principal executive offices are located at 46, avenue de la Grande Armée, 75017 Paris, France.
Filing Stats: 182 words · 1 min read · ~1 pages · Grade level 14 · Accepted 2025-12-29 06:22:22
Filing Documents
- d65502d6k.htm (6-K) — 8KB
- d65502dex991.htm (EX-99.1) — 16KB
- g65502g1224151629333.jpg (GRAPHIC) — 3KB
- g65502sanofi.jpg (GRAPHIC) — 3KB
- 0001193125-25-332163.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: December 29, 2025 SANOFI By /s/ Alexandra Roger Name: Alexandra Roger Title: Head of Legal Corporate & Finance 3